ArticleWFUMB ultrasound open2024
Methods and Validation of Velacur Determined Fat Fraction in patients with MASLD.
Article in WFUMB ultrasound open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accuracy of Velacur in Assessing MASLD and MASH Patients Using Biopsy as the Gold Standard.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Introduction: As prevalence of patients with steatotic liver diseases increases throughout the world, it is necessary to have accurate and accessible methods to estimate liver fat content. Using quantitative ultrasound parameters, such as attenuation and backscatter, it is possible to estimate liver fat, with MRI proton density fat fraction as the reference standard. Velacur determined fat fraction (VDFF) is a new output measurement on Velacur (Sonic Incytes Medical Corp, Vancouver, BC). Methods: This study described the results of parameter fitting and validation of VDFF, which is a combination of quantitative ultrasound parameters. Patients were recruited from sites within the US and Canada. All patients had contemporaneous Velacur and MRI proton density fat fraction scans. The quantitative ultrasound parameter fitting was completed using linear regression on a random sub-sample approach, and a separate cohort was used for validation. The AUC for detection of 5% liver fat based on MRI-PDFF and the correlation between MRI-PDFF and VDFF was measured in both cohorts. Results: VDFF had an AUROC of 0.97 for the detection of MRI-PDFF > 5% in the parameter fitting cohort, and 0.99 in the validation cohort. The correlation [95% CI] between MRI-PDFF and VDFF was r = 0.84 [0.78 - 0.89] for the parameter fitting cohort and r = 0.90 [0.82 - 0.95] for the validation cohort. Conclusion: The Velacur Determined Fat Fraction (VDFF) is an accurate and accessible way to estimate steatosis as measured by MRI-PDFF. Velacur VDFF can fill the unmet need of an accurate means to diagnosis hepatic steatosis and serve as a potential alternative to biopsy or MRI-PDFF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.